Literature DB >> 27183493

Adequately-Sized Nanocarriers Allow Sustained Targeted Drug Delivery to Neointimal Lesions in Rat Arteries.

Ryosuke Taniguchi1, Yutaka Miura2, Hiroyuki Koyama1,3, Tsukasa Chida4, Yasutaka Anraku4, Akihiro Kishimura5,6, Kunihiro Shigematsu1, Kazunori Kataoka2,4,7, Toshiaki Watanabe1.   

Abstract

In atherosclerotic lesions, the endothelial barrier against the bloodstream can become compromised, resulting in the exposure of the extracellular matrix (ECM) and intimal cells beneath. In theory, this allows adequately sized nanocarriers in circulation to infiltrate into the intimal lesion intravascularly. We sought to evaluate this possibility using rat carotid arteries with induced neointima. Cy5-labeled polyethylene glycol-conjugated polyion complex (PIC) micelles and vesicles, with diameters of 40, 100, or 200 nm (PICs-40, PICs-100, and PICs-200, respectively) were intravenously administered to rats after injury to the carotid artery using a balloon catheter. High accumulation and long retention of PICs-40 in the induced neointima was confirmed by in vivo imaging, while the accumulation of PICs-100 and PICs-200 was limited, indicating that the size of nanocarriers is a crucial factor for efficient delivery. Furthermore, epirubicin-incorporated polymeric micelles with a diameter similar to that of PICs-40 showed significant curative effects in rats with induced neointima, in terms of lesion size and cell number. Specific and effective drug delivery to pre-existing neointimal lesions was demonstrated with adequate size control of the nanocarriers. We consider that this nanocarrier-based drug delivery system could be utilized for the treatment of atherosclerosis.

Entities:  

Keywords:  atherosclerosis; drug delivery; epirubicin; nanocarrier; nanoparticle; neointimal hyperplasia

Mesh:

Substances:

Year:  2016        PMID: 27183493     DOI: 10.1021/acs.molpharmaceut.6b00219

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  4 in total

1.  Endothelial Cell TGF-β (Transforming Growth Factor-Beta) Signaling Regulates Venous Adaptive Remodeling to Improve Arteriovenous Fistula Patency.

Authors:  Ryosuke Taniguchi; Yuichi Ohashi; Jung Seok Lee; Haidi Hu; Luis Gonzalez; Weichang Zhang; John Langford; Yutaka Matsubara; Bogdan Yatsula; George Tellides; Tarek M Fahmy; Katsuyuki Hoshina; Alan Dardik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-05-05       Impact factor: 10.514

2.  Reactive oxygen species (ROS)-responsive size-reducible nanoassemblies for deeper atherosclerotic plaque penetration and enhanced macrophage-targeted drug delivery.

Authors:  Jianhua He; Wenli Zhang; Xiaoju Zhou; Fengfei Xu; Jiahui Zou; Qiqi Zhang; Yi Zhao; Hongliang He; Hu Yang; Jianping Liu
Journal:  Bioact Mater       Date:  2022-04-07

Review 3.  Mouse models of atherosclerosis: a historical perspective and recent advances.

Authors:  Yee Ting Lee; Hiu Yu Lin; Yin Wah Fiona Chan; Ka Hou Christien Li; Olivia Tsz Ling To; Bryan P Yan; Tong Liu; Guangping Li; Wing Tak Wong; Wendy Keung; Gary Tse
Journal:  Lipids Health Dis       Date:  2017-01-17       Impact factor: 3.876

4.  Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors.

Authors:  Xiaopin Duan; Christina Chan; Wenbo Han; Nining Guo; Ralph R Weichselbaum; Wenbin Lin
Journal:  Nat Commun       Date:  2019-04-23       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.